Enfermedad inflamatoria intestinal como efecto paradójico del tratamiento con anti-TNF-α

Iriarte, Ainara; Zaera, Celia; Bachiller‐Corral, Javier; López-Sanromán, Antonio

doi:10.1016/j.gastrohep.2016.01.011

Cited by 20 publications

(3 citation statements)

References 17 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ECCO guidelines recommend implementing a case-by-case decision model before starting NSAID treatment, carefully considering the pros and the cons of such treatment. In cases refractory to standard treatment, the use of TNFα-antagonists is recommended, with the exclusion of etanercept, due to reported cases of paradoxical gastrointestinal inflammation [10,11]. ECCO guidelines state that JAK inhibitors may be used in axSpA due to their efficacy in ankylosing spondylitis [10].…”

Section: Management Of Axial Spondyloarthropathymentioning

confidence: 99%

Latest Treatment Perspectives for IBD-related Arthritis - a review

Sęk,

Duchnevič,

Galasińska

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: IBD-related arthritis (spondyloarthropathy) is the most common extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD) and is often considered a formidable clinical challenge. Emergence of TNFα-antagonists has revolutionised the clinical approach to management of IBD-related arthritis and remains the mainstay of the therapy. However, its use presents several limitations, underscoring the need for new treatment modalities. Recently, new agents have been approved for the management of IBD, although their influence on IBD-related arthritis has been scarcely investigated. Aim of the Study: The aim of the study was to collect and analyse current literature regarding the efficacy of new agents used for treating IBD-related arthritis. Methods and Materials: Extensive research was conducted using the PubMed, ScienceDirect database and Google Scholar, with the primary focus on literature from the past 5 years. Firstly, potential novel treatment options for IBD-related arthritis were obtained. The names of the drugs were juxtaposed with terms related to “IBD-related arthritis” to gather data regarding their efficacy in said condition. Additionally, references from selected articles were included in the analysis. Results: Emerging treatment options show promising results in achieving remission of IBD-related arthritis. However, our study revealed research gap as the current literature lacks large-scale, prospective studies that assess the efficacy of the aforementioned agents in achieving a resolution of IBD-related arthritis. Therefore, the results of our study encourage further research, with special emphasis on large-scale randomised controlled trials.

show abstract

Section: Management Of Axial Spondyloarthropathymentioning

confidence: 99%

Latest Treatment Perspectives for IBD-related Arthritis - a review

Sęk,

Duchnevič,

Galasińska

et al. 2024

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…Etanercept has also been implicated in the emergence of paradoxical IBD, meaning it can produce symptoms similar to those it is used to treat. 58 Dallocchio et al . 59 reported eight cases of IBD following etanercept therapy for idiopathic juvenile arthritis.…”

Section: Anti-tnf Agents In Intestinal Behçet’s Disease: the Current mentioning

confidence: 99%

Anti-Tumor Necrosis Factor Therapy in Intestinal Beh Ccedil;et rsquo;s Disease

Park

Cheon

2018

Gut and Liver

View full text Add to dashboard Cite

Intestinal Behçet’s disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet’s disease is difficult to treat and often requires surgery because of the failure of conventional medical treatment. Administration of anti-tumor necrosis factor–α, a potential therapeutic strategy, is currently under active clinical investigation, and evidence of its effectiveness for both intestinal Behçet’s disease and inflammatory bowel diseases has been accumulating. Here, we review updated data on current experiences and outcomes after the administration of anti-tumor necrosis factor–α for the treatment of intestinal Behçet’s disease. In addition to infliximab and adalimumab, which are the most commonly used agents, we describe agents such as golimumab, etanercept, and certolizumab pegol, which have recently been shown to be effective in refractory intestinal Behçet’s disease. This review also discusses safety issues associated with anti-tumor necrosis factor–α, including vulnerability to infections and malignancy.

show abstract

“…However, drugs that target NF-kB can actually wind up having paradoxical effects due to the complexity of NF-kB cell signaling in inflammation and cancer (Hoesel and Schmid, 2013). Specifically, some drugs can unwittingly unmask or induce diseases similar to those they were intended to treat (Iriarte et al, 2017). Our inability to predict the effect of drugs on the NF-kB network stems from the fact that we do not completely understand its internal and external interactions.…”

mentioning

confidence: 99%